10th Aggregate Spend and Open Payments Conference

Memo

The demand for transparency when looking at the relationship between life science manufacturers and health care providers is at an all-time high. Recent updates to the Physicians Payments Sunshine Act will increase the scope of responsibilities for manufacturers and HCPs alike.Enforcement in the industry is constantly evolving on state, federal and global levels. With differences in reporting requirements, it is up to manufacturers to manage risk, maintain transparency and ensure compliance at all times, which can be extremely difficult. ExL Events is proud to bring you the 10th Aggregate Spend and Open Payments Conference. Over the past nine years, we have had the privilege of educating over 223 organizations and will continue to provide thought-provoking sessions, interactive panels, and spotlight sessions this year. Top Five Reasons to Attend1. Explore Sunshine Act and Open Payments System updates with the Centers for Medicare and Medicaid Services Director, Robin Usi2. Interact with DOJ representatives and in-house counsel members to discuss the current enforcement landscape3. Gain insight from 20+ expert speakers from various backgrounds, including speakers from Boehringer Ingelheim, Daiichi Sankyo, Bayer, Otsuka, Chiesi, Shinogi and more4. Discuss the best practices for identifying, collecting, and analyzing the data required for open payments reporting5. Investigate emerging trends and high-risk areas including federal, state and global policies, privacy implications, price transparency, and ethical considerations URLs:Tickets:  https://go.evvnt.com/371077-1?pid=5569 Brochure: https://go.evvnt.com/371077-3?pid=5569  Date and Time: On Tuesday June 18, 2019 at 8:00 am ends Wednesday June 19, 2019 at 6:00 pm Venue details: The Inn at Penn, a Hilton Hotel, 3600 Sansom Street, Philadelphia, 19104, United States Prices:Early Bird Pricing - Register by May 3, 2019: USD 1895.0,Standard Pricing: USD 2095.0,Onsite Pricing: USD 2295.0 Speakers: Isha Arora, Compliance Consultant, Bernard Cooney, Assistant United States Attorney, District of New Jersey, U.S. DEPARTMENT OF JUSTICE, Charlene E. Davis, Esq. Associate Vice President and Head of Healthcare Compliance North America, SUN PHARMACEUTICAL INDUSTRIES, Nicodemo Fiorentino, Esq. Senior Manager, Compliance Operations and Transparency, SUN PHARMA, Daniel Font, CIIP-US, CIPM Director, Compliance Investigations, Policy and Training, DAIICHI SANKYO, Bill Friedrich, Senior Manager, Compliance, HIKMA PHARMACEUTICALS , Kari K. Loeser, U.S. Healthcare Compliance Officer, RELYPSA, Joseph Mack, Senior Compliance Counsel, BAYER, Heather McCollum, J.D., MHA, CCEP-I Director, Compliance, SHIONOGI, Natalia Morozkina, Compliance Manager, OTSUKA PHARMACEUTICAL COMPANIES, Sharon Muscato, Director, Transparency and Compliance Operations, ALEXION PHARMACEUTICALS, Margaret Rossini, Director, Corporate Compliance and Monitoring Risk, SANDOZ, Stephen Shoop, Life Sciences Compliance Manager, FUJIFILM HOLDINGS AMERICA CORPORATION, Avi Spira, Chief Compliance, Risk and Privacy Officer, FUJIFILM HOLDINGS AMERICA CORPORATION, Bryan Stefanski, Compliance Director, SIEMENS HEALTHCARE, Bryan Stinehour, Product Manager, MEDISPEND , Sheea Sybblis, Senior Counsel, BOEHRINGER INGELHEIM , Robin Usi, Director, Division of Data and Informatics, Center for Program Integrity, CENTERS FOR MEDICARE and MEDICAID SERVICES, Amy Valiante, Ross Vice President, Contracts and Compliance, CHIESI USA, Donna White, Vice President, Contracts and Compliance, CHIESI USA